Global Meniere Disease Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Meniere Disease treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Orbis Biosciences Inc, Otonomy Inc, Quark Pharmaceuticals Inc, Sound Pharmaceuticals Inc, Synphora AB and others.
A Significant contribution to the Meniere Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Meniere Disease pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Meniere Disease condition and increased access to investments is encouraging growth of Meniere Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Meniere Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Meniere Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Meniere Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Meniere Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Meniere Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Meniere Disease pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Meniere Disease Pipeline candidates-
A Significant contribution to the Meniere Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Meniere Disease pipeline included 5 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Meniere Disease condition and increased access to investments is encouraging growth of Meniere Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Meniere Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Meniere Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Meniere Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Meniere Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Meniere Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Meniere Disease pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Meniere Disease Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Meniere Disease drugs
- Late phase: Phase 3 and in-approval Meniere Disease drugs
- Company overview
- Snapshot
- Meniere Disease therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Meniere Disease- Disease Overview
2.2 Meniere Disease- Pipeline Snapshot
2.3 Meniere Disease- Pipeline Drugs by Phase
2.4 Meniere Disease- Pipeline Drugs by Company
2.5 Meniere Disease- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Orbis Biosciences Inc Meniere Disease Drug Pipeline, H2- 2019
3.2 Otonomy Inc Meniere Disease Drug Pipeline, H2- 2019
3.3 Quark Pharmaceuticals Inc Meniere Disease Drug Pipeline, H2- 2019
3.4 Sound Pharmaceuticals Inc Meniere Disease Drug Pipeline, H2- 2019
3.5 Synphora AB Meniere Disease Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Meniere Disease- Phase 1 Drug Details
4.2 Meniere Disease- Phase 1 Drug Overview
4.3 Meniere Disease- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Meniere Disease- Phase 2 Drug Details
5.2 Meniere Disease- Phase 2 Drug Overview
5.3 Meniere Disease- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Meniere Disease- Phase 3 Drug Details
6.2 Meniere Disease- Phase 3 Drug Overview
6.3 Meniere Disease- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Meniere Disease- Pre-clinical Phase Drug Details
7.2 Meniere Disease- Pre-clinical Phase Drug Overview
7.3 Meniere Disease- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Meniere Disease- Disease Overview
2.2 Meniere Disease- Pipeline Snapshot
2.3 Meniere Disease- Pipeline Drugs by Phase
2.4 Meniere Disease- Pipeline Drugs by Company
2.5 Meniere Disease- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Orbis Biosciences Inc Meniere Disease Drug Pipeline, H2- 2019
3.2 Otonomy Inc Meniere Disease Drug Pipeline, H2- 2019
3.3 Quark Pharmaceuticals Inc Meniere Disease Drug Pipeline, H2- 2019
3.4 Sound Pharmaceuticals Inc Meniere Disease Drug Pipeline, H2- 2019
3.5 Synphora AB Meniere Disease Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Meniere Disease- Phase 1 Drug Details
4.2 Meniere Disease- Phase 1 Drug Overview
4.3 Meniere Disease- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Meniere Disease- Phase 2 Drug Details
5.2 Meniere Disease- Phase 2 Drug Overview
5.3 Meniere Disease- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Meniere Disease- Phase 3 Drug Details
6.2 Meniere Disease- Phase 3 Drug Overview
6.3 Meniere Disease- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Meniere Disease- Pre-clinical Phase Drug Details
7.2 Meniere Disease- Pre-clinical Phase Drug Overview
7.3 Meniere Disease- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
